Day: November 12, 2021

Advancing Phase 1b study of VIP152 in MYC-driven relapsed or refractory aggressive lymphomas and advanced solid tumors Phase 1b dose escalation study of VIP152 in patients with CLL relapsed/refractory to venetoclax and BTK inhibitors on track to initiate in 2H2021 Strengthened balance sheet with $50M private placement PALO ALTO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) —  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update. “Our Phase 1b study of VIP152 continues to enroll across diverse indications per our development plan. Despite the recent COVID surge, we remain on-track with our goal to initiate...

PRT543 and PRT811 Demonstrate Favorable Safety Profile, Tolerability and Evidence of Preliminary Clinical Activity in Phase 1 Dose Escalation in Unselected Patients Phase 1 Dose Expansion Ongoing in Biomarker-Selected Solid Tumor and Hematologic Malignancy Expansion Cohorts for PRT543; Dose Expansion Portion of Phase 1 Trial of PRT811 to Commence 4Q21 with Data Readouts Anticipated for Both Programs in 2022 PRT2527 IND Cleared by FDA; Phase 1 Clinical Trial Evaluating IV Monotherapy in Patients with Selected Solid Tumors Anticipated to Begin by Year-End Strong Cash, Cash Equivalents and Marketable Securities Position of $320 Million to Support Clinical and Discovery Pipeline Advancement WILMINGTON, Del., Nov. 12, 2021 (GLOBE NEWSWIRE) — Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today...

Reports early patient mortality data in Tigris Trial on target with expectations TORONTO, Nov. 12, 2021 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (Dialco), today announced its financial results for the third quarter ended September 30, 2021, and provided a corporate update. Chris Seto, CEO of Spectral, commented, “We are pleased to report progress on the clinical development of Toraymyxin™ (“PMX”), though the direct impact of covid outbreaks continue to correlate to decreased enrollment. As we entered Q3 2021, enrollment activity ramped up significantly...

Continues to progress Phase 1b randomized, double-blind, placebo-controlled trial of ALRN-6924 in patients with p53-mutated non-small cell lung cancer (NSCLC) undergoing chemotherapyUpdated planned NSCLC study data readouts include interim results in 2Q22; topline full results in 4Q22  Reported preliminary data on ALRN-6924’s p21-mediated cell cycle arrest in healthy humansConfirmed biomarker-driven mechanism of action Characterized time to onset, magnitude and duration of cell cycle arrest, informing potential universal dose and schedule across distinct chemotherapy regimens        $52.2 million cash and cash equivalents as of September 30, 2021, expected to fund operations into second half of 2023BOSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) — Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused...

Contract Manufacturer identified in prior CRL receives satisfactory resolution (VAI) of the facility’s identified deficiencies from the FDA Verrica is engaging with the FDA on next steps toward potential approval of VP-102 for the treatment of molluscum contagiosum WEST CHESTER, Pa., Nov. 12, 2021 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the third quarter ended September 30, 2021. “We are pleased that the issues identified at the CMO unrelated to VP-102 have been successfully resolved, enabling us to move toward approval,” said Ted White, Verrica’s President and Chief Executive Officer. “We remain confident in VP-102’s commercial potential. There...

Record Results Driven by 122% Increase in Year-Over-Year Fee Paying Assets Under Management DALLAS, Nov. 12, 2021 (GLOBE NEWSWIRE) —  P10, Inc. (NYSE: PX), a leading private markets solutions provider, today reported financial results for the third quarter ended September 30, 2021. Third Quarter 2021 Financial Highlights:Fee Paying Assets Under Management: $16.3 billion as of the end of the quarter, a 122% increase year-over-year Revenue: $38.1 million for the quarter, a 148% increase year-over-year Net Income: $4.1 million for the quarter, a $4 million increase year-over-year Net Income attributable to P10: $3.6 million for the quarter, a $3.7 million increase year-over-year Adjusted EBITDA: $21.8 million for the quarter, a 148% increase year-over-year Adjusted Net Income: $16.2 million for the quarter, a 146% increase year-over-year Earnings...

— Completed business combination with Alpha Healthcare Acquisition Corp. and raised $242M in proceeds — — Progressed advanced-stage clinical- and early-stage programs of the human acellular vessel (HAV™) and other engineered tissue platform applications — DURHAM, N.C., Nov. 12, 2021 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced financial results for the third quarter ended September 30, 2021, and highlighted recent corporate accomplishments. “Humacyte has made great strides advancing our bioengineered tissue platform to create novel human acellular tissues and organs. This quarter was marked with significant corporate progress, including the closing of our...